SCHEMBL17809671

SCHEMBL17809671

CNC(=O)c1ccc(-c2cc3c(cn2)N(C)CCC3)cn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.47
USP30 Q70CQ3 1/20 0.43
SCD O00767 1/20 0.43
CREBBP Q92793 3/20 0.42
BRD4 O60885 2/20 0.42
FGFR1 P11362 2/20 0.42
FGFR4 P22455 2/20 0.42
CYP11B2 P19099 2/20 0.41
HRH3 Q9Y5N1 1/20 0.41
OTUD7B Q6GQQ9 2/20 0.41
KCNH2 Q12809 1/20 0.40
PIP5K1C O60331 1/20 0.39
PIK3CA P42336 1/20 0.39
PI4KA P42356 1/20 0.39
PI4KB Q9UBF8 1/20 0.39
PRKAB2 O43741 1/20 0.39
PRKAG1 P54619 1/20 0.39
PRKAA2 P54646 1/20 0.39
PRKAA1 Q13131 1/20 0.39
PRKAG3 Q9UGI9 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17809553 0.87 OTUD7B (0.48) MAPTUSP30SCDCREBBPBRD4
SCHEMBL19368737 0.86 CREBBP (0.42) MAPTUSP30SCDCREBBPBRD4
SCHEMBL17809789 0.84 CREBBP (0.44) MAPTUSP30SCDCREBBPBRD4
SCHEMBL17809596 0.82 CREBBP (0.43) MAPTUSP30SCDCREBBPBRD4
SCHEMBL17794572 0.81 CREBBP (0.59) CREBBPBRD4
SCHEMBL19369015 0.76 OTUD7B (0.46) USP30SCDCREBBPBRD4CYP11B2
SCHEMBL17806301 0.73 CREBBP (0.45) USP30SCDCREBBPBRD4CYP11B2
SCHEMBL17794573 0.71 PIM1 (0.44) MAPTCREBBPCYP11B2
SCHEMBL17806331 0.71 CREBBP (0.43) USP30SCDCREBBPBRD4FGFR4
SCHEMBL19368895 0.71 CREBBP (0.58) CREBBPBRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3224258-B1 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-C]PYRIDIN-3-AMINE COMPOUNDS AS CBP AND/OR EP300 INHIBITORS GENENTECH INC (US) 2019-08-14 EP disclosed
US-20170333406-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2017-11-23 US disclosed
US-9763922-B2 Therapeutic compounds and uses thereof GENENTECH, INC. (US) 2017-09-19 US disclosed
US-20160158207-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2016-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170333406-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF EP300, HDAC1, HDAC10 MAPT 3833/4885USP30 2156/4885SCD 3743/4885
US-20160158207-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF EP300, HDAC1, HDAC10 MAPT 3833/4885USP30 2156/4885SCD 3743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.